Patient Data and Results of Second Transplants
| Years of Transplant Group Denomination . | 1970-1976 Group 1 . | 1977-1981 Group 2 . | 1982-1996 Group 3 . |
|---|---|---|---|
| No. of patients studied | 22 | 10 | 12 |
| Median age in years (range) | 19.2 (3.2-53.7) | 20.3 (6.8-37.4) | 10.6 (2.5-51.8) |
| Median days between transplants (range) | 37 (24-179) | 57 (23-98) | 226 (44-743) |
| Preparative regimen | |||
| CY 200 mg/kg + procarbazine + ATG 36 mg/kg | 9 | 0 | 0 |
| TBI-based regimen | 12 | 0 | 2 |
| CY 200 mg/kg + ATG 90 mg/kg | 0 | 10 | 9 |
| Other | 1* | 0 | 1† |
| GVHD prophylaxis (no. of patients) | |||
| MTX | 22 | 10 | 0 |
| MTX + cyclosporine | 0 | 0 | 12 |
| Median marrow cell dose ×108/kg (range) | 2.1 (0.8-4.4) | 2.7 (1.9-12.2) | 4.5 (1.47-10.1) |
| PBSC (CD34+ cells ×106/kg) | 0 | 0 | 1 (11) |
| Buffy coat cell infusion (no. of patients) | 8 | 10 | 4 |
| No. of patients (%) | |||
| Unevaluable‡ | 8 (36.4) | 0 | 1 (8.4) |
| With rejection | 8 (36.4) | 5 (50) | 3 (25) |
| With sustained engraftment | 6 (27.2) | 5 (50) | 8 (66.7) |
| GVHD (no. of patients) | |||
| Acute, grades 2-4 | 2 | 5 | 2 |
| Chronic | 0 | 4 | 4 |
| Survival at 10 years (%) | 5% | 20% | 83% |
| No. of patients surviving | 1 | 2 | 10 |
| Median years survival after second transplant (range) | |||
| Surviving patients | 15.6 | 14.3 (10.6, 18.1) | 10.0 (2.8-12.2) |
| Patients who died | 0.06 (0.01-0.39), | 0.39 (0.05-10.1), | 0.28 (0.01-0.54), |
| n = 21 | n = 8 | n = 2 |
| Years of Transplant Group Denomination . | 1970-1976 Group 1 . | 1977-1981 Group 2 . | 1982-1996 Group 3 . |
|---|---|---|---|
| No. of patients studied | 22 | 10 | 12 |
| Median age in years (range) | 19.2 (3.2-53.7) | 20.3 (6.8-37.4) | 10.6 (2.5-51.8) |
| Median days between transplants (range) | 37 (24-179) | 57 (23-98) | 226 (44-743) |
| Preparative regimen | |||
| CY 200 mg/kg + procarbazine + ATG 36 mg/kg | 9 | 0 | 0 |
| TBI-based regimen | 12 | 0 | 2 |
| CY 200 mg/kg + ATG 90 mg/kg | 0 | 10 | 9 |
| Other | 1* | 0 | 1† |
| GVHD prophylaxis (no. of patients) | |||
| MTX | 22 | 10 | 0 |
| MTX + cyclosporine | 0 | 0 | 12 |
| Median marrow cell dose ×108/kg (range) | 2.1 (0.8-4.4) | 2.7 (1.9-12.2) | 4.5 (1.47-10.1) |
| PBSC (CD34+ cells ×106/kg) | 0 | 0 | 1 (11) |
| Buffy coat cell infusion (no. of patients) | 8 | 10 | 4 |
| No. of patients (%) | |||
| Unevaluable‡ | 8 (36.4) | 0 | 1 (8.4) |
| With rejection | 8 (36.4) | 5 (50) | 3 (25) |
| With sustained engraftment | 6 (27.2) | 5 (50) | 8 (66.7) |
| GVHD (no. of patients) | |||
| Acute, grades 2-4 | 2 | 5 | 2 |
| Chronic | 0 | 4 | 4 |
| Survival at 10 years (%) | 5% | 20% | 83% |
| No. of patients surviving | 1 | 2 | 10 |
| Median years survival after second transplant (range) | |||
| Surviving patients | 15.6 | 14.3 (10.6, 18.1) | 10.0 (2.8-12.2) |
| Patients who died | 0.06 (0.01-0.39), | 0.39 (0.05-10.1), | 0.28 (0.01-0.54), |
| n = 21 | n = 8 | n = 2 |